key: cord-0928550-zh68ok5v
authors: Scudiero, Fernando; Silverio, Angelo; Di Maio, Marco; Russo, Vincenzo; Citro, Rodolfo; Personeni, Davide; Cafro, Andrea; D'Andrea, Antonello; Attena, Emilio; Pezzullo, Salvatore; Canonico, Mario Enrico; Galasso, Gennaro; Pitì, Antonino; Parodi, Guido
title: Pulmonary embolism in COVID-19 patients: Prevalence, predictors and clinical outcome
date: 2020-11-17
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.11.017
sha: a303489713b266b1bcd707de19ed3cd6d35cb180
doc_id: 928550
cord_uid: zh68ok5v

INTRODUCTION: The incidence, characteristics, and prognosis of pulmonary embolism (PE) in Coronavirus disease 2019 (COVID-19) have been poorly investigated. We aimed to investigate the prevalence and the correlates with the occurrence of PE as well as the association between PE and the risk of mortality in COVID-19. METHODS: Retrospective multicenter study on consecutive COVID-19 patients hospitalized at 7 Italian Hospitals. At admission, all patients underwent medical history, laboratory and echocardiographic evaluation. RESULTS: The study population consisted of 224 patients (mean age 69 ± 14, male sex 62%); PE was diagnosed in 32 cases (14%). Patients with PE were hospitalized after a longer time since symptoms onset (7 IQR 3–11 days, 3 IQR 1–6 days; p = 0.001) and showed higher D-dimers level (1819 IQR 568–5017 ng/ml vs 555 IQR 13–1530 ng/ml; p < 0.001) and higher prevalence of myocardial injury(47% vs 28%, p = 0.033). At multivariable analysis, tricuspid annular plane systolic excursion (TAPSE; HR = 0.84; 95% CI 0.66–0.98; p = 0.046) and systolic pulmonary arterial pressure (sPAP; HR = 1.12; 95% CI 1.03–1.23; p = 0.008) resulted the only parameters independently associated with PE occurrence. Mortality rates (50% vs 27%; p = 0.010) and cardiogenic shock (37% vs 14%; p = 0.001) were significantly higher in PE as compared with non-PE patients. At multivariate analysis PE was significant associated with mortality. CONCLUSION: PE is relatively common complication in COVID-19 and is associated with increased mortality risk. TAPSE and sPAP resulted the only parameters independently associated with PE occurrence in COVID-19 patients.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human coronavirus recently recognized as the cause of the coronavirus disease 2019 . The outbreak sparked in Wuhan, capital city of Hubei province in China, and spread rapidly to other countries, reaching devastating pandemic proportion. Although knowledge on the pathophysiology and on the clinical features of COVID-19 is growing fast, [1] the patient management remains largely empirical or based on observations from retrospective studies, small series, and single case reports.

An increasing numbers of studies have showed abnormal serum coagulation parameters in hospitalized patients with severe forms of COVID-19; [2] moreover, a single-center study conducted by using computed tomography (CT) scan demonstrated the presence of pulmonary thrombi in patients with SARS-CoV-2 related pneumonia. [3] Elevated D-dimer levels were strongly associated with inhospital mortality, [4] and non survivors among infected patients met clinical criteria for disseminated intravascular coagulation (DIC). [2] In addition, prolonged immobilization in critically ill patients promotes venous stasis and increases the risk of thromboembolic events. [5] Of note, anticoagulant treatment has been associated with lower risk of mortality in patients with severe COVID-

This is a multi-center observational study including consecutive patients with COVID-19 enrolled at 7 Italian Hospitals (Bergamo, Naples, Sassari and Salerno provinces) contributing to COVID-19 Italian Network (Cov-IT Network) from

February 28 th to April 20 th , 2020. COVID-19 diagnosis was initially based on the World Health Organization criteria and all cases were later confirmed by realtime reverse transcriptase-polymerase chain reaction analysis of throat swab specimens. [7] All patients included in this study were evaluated by the hospital cardiology service and underwent transthoracic echocardiography (TTE) during hospitalization.

This study was conducted according to the Declaration of Helsinki and approved by the institutional ethics committees. The requirement for informed consent from individual patients was waived due to the observational retrospective design of this study.

TTE was performed in accordance with the current guidelines. [8] Left ventricular systolic function was assessed by determining left ventricular ejection fraction (LVEF) through biplane analysis using the modified Simpson's rule. As a parameter of global right ventricular (RV) function, tricuspid annular plane systolic excursion (TAPSE), which reflects the base to apex shortening of the RV in systole, was assessed. RV dysfunction was defined in accordance with the current guidelines. [8] Systolic pulmonary artery pressure (sPAP) was derived from the tricuspid regurgitant jet velocity using systolic trans-tricuspid pressure gradient calculated by the modified Bernoulli equation and the addition of estimated right atrial pressure according to inferior vena cava dimension and inspiratory distensibility. [8] Pulmonary hypertension based on echocardiographic findings are defined according to European Society of Cardiology (ESC) guidelines. [9] J o u r n a l P r e -p r o o f The primary objective of this study was to describe the prevalence of PE in this multi-center cohort and to identify the clinical, laboratory and echocardiographic parameters correlated to this condition during hospitalization. Secondary objective was to assess the association between PE and the risk of in-hospital mortality.

The number of patients who had died, had been discharged, or were still hospitalized as of May 8 th , 2020, date of the analysis, were recorded. The length of hospitalization was also determined.

Distribution of continuous data was assessed with the Kolmogorov-Smirnov test.

Normally distributed variables were expressed as mean±standard deviation, whereas non-normal distributed ones as median and interquartile range. Categorical variables were reported as numbers and percentages. Continuous normallydistributed variables were compared by using the Student t-test; differences between non-normally distributed variables were tested with the Mann-Whitney U test. Categorical variables were compared with chi-squared test, or Fisher exact test, when appropriate. Receiver operating characteristic (ROC) curve analysis were performed to identify the best cutoff values of the D-dimer and highsensitivity troponin of PE. Optimal threshold value was determined by using the Younden's index and the area under the curve (AUC) was calculated as a measure of their diagnostic accuracy. Survival curves were generated by using the Kaplan-Meier method, and differences among groups were investigated with the Log-Rank test. Univariable and multivariable logistic regression analyses were performed to evaluate the individual and independent association of clinical and echocardiographic variables with the occurrence of PE, and presented as odds ratio (OR) with by their 95% confidence intervals (CI). Multicollinearity was assessed using collinearity diagnostics. The variance inflation factors showed no J o u r n a l P r e -p r o o f Journal Pre-proof significant collinearity (< 2.5) among the covariates. We used a parsimonious model including variables with p<0.10 by the univariate test as a candidate for the multivariate analysis.

The risk of in-hospital death in patients with vs. those without PE was calculated using the Cox proportional hazard regression model and presented as unadjusted and adjusted hazard ratios (HR) with 95% confidence intervals. To account for potential confounders related to the severity of the disease, we performed a multivariable covariates adjustment for age, LVEF, ARDS, and cardiac injury. Model goodness of fit was assessed with Hosmer-Lemeshow test. A p-value < 0.05 was considered significant. All tests were two-sided. Analyses were performed with SPSS statistical package, Version 21 (IBM Corp., Armonk, NY, USA).

During the study period, overall 1393 patients for fever and dyspnea were admitted at investigating centers. Of them, 224 consecutive patients (16%) with confirmed diagnosed of COVID-19, who underwent TTE during cardiology consultation were included in the final analysis. The main baseline characteristics of the study population are summarized in Table 1 . The population mean age was 69±14, and male sex rate was 62%. PE was diagnosed in 32 cases (14%). No difference in terms of clinical presentation was reported among groups. Although not statistically significant, PE patients showed lower prevalence of AF (12% vs 22%; p= 0.220) and of anticoagulation therapy before hospital admission (12% vs 20%; p= 0.3280). Use of heparin was reported in 81% of the overall population; no statistical differences in the use of anticoagulant and other pharmacological therapies was showed among groups.

Patients with PE were hospitalized after a longer time since symptom onset (7 IQR 11-3 days vs 3 IQR 1-6 days in PE and non-PE patients, respectively; p= 0.001) and, therefore, in a later infectious phase (30% vs 13%; p= 0.018). Time between symptom onset and hospitalization was able to discriminate PE (AUC 0.71, CI 95% 0.61-0.78, p <0.001) with a best cutoff of 7 days (sensitivity = 68%; specificity = 50%).

There was no difference in terms of NT-pro-BNP values among groups (4076 ± 3402 pg/ml vs 4765 ± 3654 pg/ml; p= 0.782). Conversely, serum levels of Ddimer (1819 IQR 568-5017 ng/ml vs 555 IQR 13-1530 ng/ml; p<0.001) and of high-sensitivity troponin (400 IQR 91-2514 n·99 th percentile vs 22 IQR 2-81 n·99 th percentile; p= 0.001) were significantly higher in PE as compared to non-PE group. D-dimer level showed a good discriminative ability for PE in hospitalized patients with COVID-19 (AUC 0.73, CI 95% 0.61-0.85, p=0.002), with a best cutoff of 1743 ng/ml (sensitivity = 63%; specificity = 76%).

There was no difference in terms of LVEF between groups ( 

The results of the logistic regression for the occurrence of PE during hospitalization are summarized in Table 3 

Follow up rate was >99%, with only 1 patient lost at follow-up. The median follow-up length was 19 days (IQR 5-27). As of May 8, 2020, date of the analysis, 24 patients (10%) were still hospitalized (4% of them in intensive care unit). The proportions of adverse events during hospitalization are summarized in Table 4 .

The percentages of death for any cause (50% vs 27%; p= 0.010), and cardiogenic shock (37% vs 14%; p= 0.001) were significantly higher in PE patients than in non-PE patients (Table 3) . Kaplan-Meier curves showed a significantly lower survival in PE than in non-PE patients (Log-Rank = 0.014; Figure 1 ). The risk of mortality was significantly higher in PE as compared with non-PE group at both unadjusted (HR 3.09, 95% CI 1.70-5.71; p <0.001) and adjusted regression model (HR 1.97, 95% CI 1.08-3.63; p=0.028). At the multivariable regression analysis, the PE emerged as a strong predictor for mortality ( Figure 1 ). The goodness of fit of the model was confirmed by the Hosmer-Lemeshow test (p=0.840).

The main findings of the present study can be summarized as follows: In the present analysis, we tested several variables potentially associated with PE, including well-known risk factors such as age or malignancy, and we found that J o u r n a l P r e -p r o o f Journal Pre-proof only TAPSE and sPAP were independently associated with the occurrence of this condition. Our study, by including patients systematically assessed by cardiologists, is the first real-world pandemic study reporting echocardiographic data in all COVID-19 patient enrolled. Echocardiography has been poorly performed in previous reports on COVID-19, which focused on the importance of clinical, computed tomography or laboratory values for PE diagnosis and prognostic stratification. [16] Of note, TTE acquisition is complex to be performed in patients infected by SARS-CoV-2 and it needs specific precautions. [17] However, TTE is the firstline imaging modality for early detection of PE, and may be diriment in patients with a well-founded suspicion by clinical and laboratory data. [13] D-dimer, cardiac injury, late hospitalization after symptoms onset, all showed a significant association with PE at univariable analyses. However, they did not confirm a significant association after adjustment for TAPSE and sPAP at the multivariable model. These results emphasize the central role of TTE for PE diagnosis, also in the COVID-19 clinical setting.

Consistently with previous data, we found a D-dimer cutoff of 1743 ng/ml, which is three-to four-fold higher than the normal threshold value (500 ng/ml) routinely adopted for PE diagnosis in the general population. [13, 18] D-dimer is usually abnormal in COVID-19, probably due to the inflammatory response induced by injury and PE. RV pressure overload due to acute PE may precipitate RV myocardium ischemia and serum release of cardiac biomarkers of necrosis. Indeed, highsensitivity troponin is a prognostic risk parameter in PE reflecting the severity of RV dysfunction and of hemodynamic derangement during the acute phase. However, cardiac injury was not significantly associated to PE at multivariable analysis, probably due to the poor specificity of high-sensitivity troponin, which it may be increased in a large proportion of patients with COVID-19 (ranging from 18.8% to 27.8%) as a consequence of multiple potential mechanisms. [20] To our knowledge, this is the first study showing an association between late hospitalization after symptom onset and PE in COVID-19. Although delay to hospitalization did not emerged as an independent correlate with PE, this finding can be a clinical parameter of interest to suspect PE in patients with COVID-19. We hypothesize that the relationship between late admission and PE can be explained by the longer bed rest, later anticoagulant prophylaxis administration as well as by the pathophysiological mechanism involved in the later phases of COVID-19 clinical course, characterized by the interplay between systemic hyper-inflammation state, [21] immuno-mediated phenomenon and clotting system activation. [22, 23] Accordingly, most PE diagnosis were confirmed within 24 hours after admission, suggesting that VTE was not related to hospitalization; probably PE in COVID-19 is a progressive pathological process, that begins in the early infection stage, when the patient is still at home, and becomes clinically manifest only in late infectious phase becoming an important cause of hospitalization.

Previous reports showed that COVID-19 patients with established cardiovascular disease and/or cardiovascular risk factors have worse prognosis and they are more likely to be admitted in intensive care unit and to need ventilatory support. [24] In the present study, we demonstrated that patients complicated by PE experienced a J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. Pharmacol Res. Epub ahead of print

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Chest CT features of COVID-19 in

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19

Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance

Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Pathophysiology and Contemporary Management of Cardiogenic Shock -A position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

D-dimer in patients infected with COVID-19 and suspected pulmonary embolism

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

The stimulation of thrombosis by hypoxia

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal

COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine

Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

Major vessel, n (%) 29 (91) Minor Vessel, n (%) 3 (9) Bilateral, n (%) 28 (87)

High, n (%) 12 (37) Intermediate-high, n (%) 3 (9) Intermediate-low, n (%) 7 (22) Low, n (%) 10 (31) PE, pulmonary embolism; ESC, European Society of Cardiology.J o u r n a l P r e -p r o o f